Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial. - He M; Jiang YZ; Gong Y; Fan L; Liu XY; Liu Y; Tang LC; Mo M; Hou YF; Di GH; Liu GY; Yu KD; et al. (BMJ (Clinical research ed.), 2024)